Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer

BACKGROUND. Effective new agents for patients with colorectal cancer (CRC) with disease progression during standard therapy regimens are needed. We hypothesized that poly ADP ribose polymerase (PARP) inhibitor therapy in patients with CRC and inefficient tumor DNA repair mechanisms, such as those wi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Leichman, Lawrence, Groshen, Susan, O’Neil, Bert H., Messersmith, Wells, Berlin, Jordan, Chan, Emily, Leichman, Cynthia G., Cohen, Steven J., Cohen, Deirdre, Lenz, Heinz-Josef, Gold, Philip, Boman, Bruce, Fielding, Anitra, Locker, Gershon, Cason, Ronald C., Hamilton, Stan R., Hochster, Howard S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2016
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746089/
https://ncbi.nlm.nih.gov/pubmed/26786262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0319
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi